- Home
- CYCN
as of 12-04-2025 3:29pm EST
$1.66
+$0.13
+8.50%
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
Chart Type:
Time Range:
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 7.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.28 - $9.47 | Next Earning Date: | 11-12-2025 |
| Revenue: | $2,855,000 | Revenue Growth: | 1371.65% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered CYCN Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 73.24%
73.24%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Cyclerion Therapeutics Inc. News
CYCN Breaking Stock News: Dive into CYCN Ticker-Specific Updates for Smart Investing
Compare CYCN vs Leading Stocks
See how CYCN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CYCN Cyclerion Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.